Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(23):1770-1771; doi:10.1093/jnci/93.23.1770-a
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hollon, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hollon, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 23, 1770-1771, December 5, 2001
© 2001 Oxford University Press

NEWS

Clinical Trial Design Changing as Molecular Targets Gain Popularity

Tom Hollon

As trends shift in cancer pharmacology, yesterday’s clinical trial designs for drugs with broad cytotoxic properties may not be appropriate for today’s targeted inhibitors of neoplastic growth.

Relatively new drug design projects include cytostatic agents, immune system modulators, and angiogenesis inhibitors. To the extent that these targeted strategies succeed, the older strategy of developing drugs with broad-spectrum cytotoxic activity may fade.

A clinical test of one of these new drugs means proving that the target is inhibited in humans and showing that cancer comes under control as a result. The Molecular Targets Faculty at the National . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?